Developer docs
API playgroundTry for free, no card

Search company profiles

Callio Therapeutics

Full company profile

uuid0000cyz

Namestring
Callio Therapeutics
Legal namestring
Callio Therapeutics, Inc.
Websiteurl
calliotx.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Callio Therapeutics, Inc. is a clinical-stage biotechnology company founded in March 2025 that develops next-generation dual-payload antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company's proprietary platform features differentiated payload and linker chemistries enabling targeted co-delivery of two drug classes to tumor cells; its lead asset CLIO-8221 is a first-in-class HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor with an ATR inhibitor, designed to overcome resistance mechanisms common with single-payload ADCs. CLIO-8221 entered a Phase I clinical trial in March 2026 in HER2-expressing solid tumors, with initial sites in Australia and the United States following FDA IND clearance and plans to expand into China pending NMPA review.

The company operates a dual-headquarters structure with its U.S. base in Seattle, Washington and an Asia-Pacific regional headquarters in Singapore. The $187 million Series A financing closed at launch, led by Frazier Life Sciences with participation from a syndicate of life sciences investors, is funding clinical proof-of-concept for CLIO-8221 and a second undisclosed ADC program. Callio is pre-revenue; its revenue model anticipates potential partnerships or direct commercialization following regulatory approval, with near-term value creation dependent on clinical readouts rather than product sales.

The leadership team is composed of operators with prior successful ADC and oncology exits, including CEO Zachary Hornby (formerly of Boundless Bio and Ignyta, which was acquired by Roche for $2 billion), CMO Naomi Hunder and CBO Kevin Hambly (both formerly of ProfoundBio, acquired by Genmab for $1.8 billion in 2024), and scientific co-founders Piers Ingram and Jerome Boyd-Kirkup, who previously co-founded Hummingbird Bioscience. The company employs between 1 and 10 staff per firmographic data and pursues a focused oncology development strategy targeting HER2-positive breast, gastric, and other HER2-expressing solid tumors, including patients who have relapsed on or are refractory to trastuzumab deruxtecan.

Short descriptiontext

Callio Therapeutics is a clinical-stage biotech developing first-in-class dual-payload antibody-drug conjugates for HER2-expressing solid tumors, with its lead program CLIO-8221 in Phase I trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multi-payload ADCs, antibody-drug conjugates, HER2 targeted therapy, oncology therapeutics, cancer biologics
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals (ADC Therapeutics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue potential from drug development through clinical proof-of-concept, with anticipated partnerships or direct commercialization following regulatory approval.

citybiz.co
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Callio Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, multi-payload antibody-drug conjugates (ADCs) featuring differentiated payload and linker technologies for targeted delivery of drug combinations to tumor cells. Its lead program CLIO-8221 is a first-in-class dual-payload HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, currently in Phase I clinical trials for HER2-expressing solid tumors. A second undisclosed ADC program is also being advanced through clinical proof-of-concept.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Wide therapeutic window with strong durable activity demonstrated in preclinical studies for CLIO-8221
Product overview1 text field

Callio Therapeutics is developing a next-generation multi-payload antibody-drug conjugate (ADC) platform and pipeline. The company's lead program is CLIO-8221, a first-in-class dual-payload HER2-targeted ADC combining topoisomerase 1 (Topo1) and ATR inhibitors to overcome resistance mechanisms common with single-payload ADCs. The company also has a second undisclosed ADC program. The platform technology enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients.

Product and service2 records
1CLIO-8221
CategoryOncology ADC (HER2-targeted clinical-stage biologic)
Description

A first-in-class dual-payload antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. It is engineered for targeted co-delivery of a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor to overcome resistance mechanisms common with single-payload ADCs, including failure after trastuzumab deruxtecan. Currently in Phase I clinical trials in Australia and the U.S.

2Second Undisclosed ADC Program
CategoryOncology ADC (undisclosed clinical-stage biologic)
Description

A second ADC program in Callio's pipeline, undisclosed as to target or payload, being advanced through clinical proof-of-concept alongside CLIO-8221 using Series A funding.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer acquired by Genmab for $1.8B in 2024. ProfoundBio developed HER2 and other ADCs with differentiated payload and linker technologies — closely comparable to Callio's platform. Several Callio executives (CMO, CBO) and board members came directly from ProfoundBio.

TypeDirect peer
Description

Clinical-stage ADC company developing next-generation antibody-drug conjugates using proprietary platforms (Dolasynthen, Immunosynthen). Competes directly with Callio in the differentiated-payload ADC space across HER2 and other oncology targets.

TypeEmerging player
Description

European biotech developing next-generation ADCs with differentiated conjugation and payload technologies. Comparable as a platform-focused ADC innovator with multiple preclinical and early clinical programs, similar in scale and stage to Callio.

TypeDirect peer
Description

Clinical-stage ADC and immuno-oncology company developing antibody-drug conjugates with novel payloads and linkers. Directly comparable as a platform ADC company pursuing differentiated payload strategies in oncology.

TypeEmerging player
Description

Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs), a distinct but adjacent ADC modality. Comparable as a novel-payload ADC platform pursuing differentiated mechanisms from conventional cytotoxic ADCs.

TypeEmerging player
Description

Germany-based ADC company developing ADCs using the cytotoxic payload amanitin. Comparable as a platform ADC company using differentiated payloads to overcome resistance — directly relevant to Callio's dual-payload thesis.

TypeEmerging player
Description

Clinical-stage ADC developer with proprietary linker-payload technology (HydraSpace/DuoBody). Comparable as a differentiated ADC platform company with HER2-targeted programs in clinical development.

TypeBroad incumbent
Description

Japanese pharmaceutical company that developed Enhertu (trastuzumab deruxtecan), the dominant HER2 ADC and standard of care in HER2-positive tumors. Sets the competitive benchmark Callio must beat in HER2-expressing tumors.

TypeBroad incumbent
Description

Pfizer acquired Seagen in 2023 for $43B, gaining Adcetris, Padcev, and Tivdak — multiple approved ADCs. Seagen's CMC and clinical ADC infrastructure established the template that newer ADC platforms like Callio's are now challenging.

TypeBroad incumbent
Description

AbbVie acquired ImmunoGen in 2024, gaining Elahere and the ADC platform that pioneered the mirvetuximab soravtansine approval. Comparable as a broad incumbent with a full ADC development platform and approved products in oncology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Callio Therapeutics

Oncology Biopharmaceuticals (ADC Therapeutics)calliotx.com

Callio Therapeutics is a clinical-stage biotech developing first-in-class dual-payload antibody-drug conjugates for HER2-expressing solid tumors, with its lead program CLIO-8221 in Phase I trials.

What Callio Therapeutics does

Callio Therapeutics, Inc. is a clinical-stage biotechnology company founded in March 2025 that develops next-generation dual-payload antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company's proprietary platform features differentiated payload and linker chemistries enabling targeted co-delivery of two drug classes to tumor cells; its lead asset CLIO-8221 is a first-in-class HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor with an ATR inhibitor, designed to overcome resistance mechanisms common with single-payload ADCs. CLIO-8221 entered a Phase I clinical trial in March 2026 in HER2-expressing solid tumors, with initial sites in Australia and the United States following FDA IND clearance and plans to expand into China pending NMPA review.

The company operates a dual-headquarters structure with its U.S. base in Seattle, Washington and an Asia-Pacific regional headquarters in Singapore. The $187 million Series A financing closed at launch, led by Frazier Life Sciences with participation from a syndicate of life sciences investors, is funding clinical proof-of-concept for CLIO-8221 and a second undisclosed ADC program. Callio is pre-revenue; its revenue model anticipates potential partnerships or direct commercialization following regulatory approval, with near-term value creation dependent on clinical readouts rather than product sales.

The leadership team is composed of operators with prior successful ADC and oncology exits, including CEO Zachary Hornby (formerly of Boundless Bio and Ignyta, which was acquired by Roche for $2 billion), CMO Naomi Hunder and CBO Kevin Hambly (both formerly of ProfoundBio, acquired by Genmab for $1.8 billion in 2024), and scientific co-founders Piers Ingram and Jerome Boyd-Kirkup, who previously co-founded Hummingbird Bioscience. The company employs between 1 and 10 staff per firmographic data and pursues a focused oncology development strategy targeting HER2-positive breast, gastric, and other HER2-expressing solid tumors, including patients who have relapsed on or are refractory to trastuzumab deruxtecan.

Callio Therapeutics firmographics

Firmographics
Name
Callio Therapeutics
Legal name
Callio Therapeutics, Inc.
Website
https://calliotx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Callio Therapeutics is a clinical-stage biotech developing first-in-class dual-payload antibody-drug conjugates for HER2-expressing solid tumors, with its lead program CLIO-8221 in Phase I trials.
Ownership category
akta.pro rank

Callio Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals (ADC Therapeutics)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Multi-payload ADCs
  • Antibody-drug conjugates
  • HER2 targeted therapy
  • Oncology therapeutics
  • Cancer biologics

Where Callio Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Callio Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: Pre-revenue clinical-stage biotech company. Revenue potential from drug development through clinical proof-of-concept, with anticipated partnerships or direct commercialization following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Callio Therapeutics product offering

Product offering

Core offering

Callio Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, multi-payload antibody-drug conjugates (ADCs) featuring differentiated payload and linker technologies for targeted delivery of drug combinations to tumor cells. Its lead program CLIO-8221 is a first-in-class dual-payload HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, currently in Phase I clinical trials for HER2-expressing solid tumors. A second undisclosed ADC program is also being advanced through clinical proof-of-concept.

Product overview

Callio Therapeutics is developing a next-generation multi-payload antibody-drug conjugate (ADC) platform and pipeline. The company's lead program is CLIO-8221, a first-in-class dual-payload HER2-targeted ADC combining topoisomerase 1 (Topo1) and ATR inhibitors to overcome resistance mechanisms common with single-payload ADCs. The company also has a second undisclosed ADC program. The platform technology enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • CLIO-8221 A first-in-class dual-payload antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. It is engineered for targeted co-delivery of a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor to overcome resistance mechanisms common with single-payload ADCs, including failure after trastuzumab deruxtecan. Currently in Phase I clinical trials in Australia and the U.S.
  • Second Undisclosed ADC Program A second ADC program in Callio's pipeline, undisclosed as to target or payload, being advanced through clinical proof-of-concept alongside CLIO-8221 using Series A funding.

Quantifiable outcome

  • Wide therapeutic window with strong durable activity demonstrated in preclinical studies for CLIO-8221

Companies that use Callio Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Callio Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Callio Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Callio Therapeutics competitors and assessment

Company assessment

Direct peers

  • ProfoundBio: Clinical-stage ADC developer acquired by Genmab for $1.8B in 2024. ProfoundBio developed HER2 and other ADCs with differentiated payload and linker technologies — closely comparable to Callio's platform. Several Callio executives (CMO, CBO) and board members came directly from ProfoundBio.
  • Mersana Therapeutics: Clinical-stage ADC company developing next-generation antibody-drug conjugates using proprietary platforms (Dolasynthen, Immunosynthen). Competes directly with Callio in the differentiated-payload ADC space across HER2 and other oncology targets.
  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing antibody-drug conjugates with novel payloads and linkers. Directly comparable as a platform ADC company pursuing differentiated payload strategies in oncology.

Emerging players

  • Tubulis: European biotech developing next-generation ADCs with differentiated conjugation and payload technologies. Comparable as a platform-focused ADC innovator with multiple preclinical and early clinical programs, similar in scale and stage to Callio.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs), a distinct but adjacent ADC modality. Comparable as a novel-payload ADC platform pursuing differentiated mechanisms from conventional cytotoxic ADCs.
  • Heidelberg Pharma: Germany-based ADC company developing ADCs using the cytotoxic payload amanitin. Comparable as a platform ADC company using differentiated payloads to overcome resistance — directly relevant to Callio's dual-payload thesis.
  • Byondis: Clinical-stage ADC developer with proprietary linker-payload technology (HydraSpace/DuoBody). Comparable as a differentiated ADC platform company with HER2-targeted programs in clinical development.

Broad incumbents

  • Daiichi Sankyo: Japanese pharmaceutical company that developed Enhertu (trastuzumab deruxtecan), the dominant HER2 ADC and standard of care in HER2-positive tumors. Sets the competitive benchmark Callio must beat in HER2-expressing tumors.
  • Pfizer (Seagen): Pfizer acquired Seagen in 2023 for $43B, gaining Adcetris, Padcev, and Tivdak — multiple approved ADCs. Seagen's CMC and clinical ADC infrastructure established the template that newer ADC platforms like Callio's are now challenging.
  • AbbVie (ImmunoGen): AbbVie acquired ImmunoGen in 2024, gaining Elahere and the ADC platform that pioneered the mirvetuximab soravtansine approval. Comparable as a broad incumbent with a full ADC development platform and approved products in oncology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Callio Therapeutics social profiles

Digital presence

Callio Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Callio Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Callio Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Callio Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Callio Therapeutics

What does Callio Therapeutics do?

Callio Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, multi-payload antibody-drug conjugates (ADCs) featuring differentiated payload and linker technologies for targeted delivery of drug combinations to tumor cells. Its lead program CLIO-8221 is a first-in-class dual-payload HER2-targeted ADC combining a topoisomerase 1 (Topo1) inhibitor and an ATR inhibitor, currently in Phase I clinical trials for HER2-expressing solid tumors. A second undisclosed ADC program is also being advanced through clinical proof-of-concept.

Is Callio Therapeutics a public or private company?

Callio Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Callio Therapeutics founded?

Callio Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is Callio Therapeutics based?

Callio Therapeutics is headquartered in Seattle, United States, in the North America region.

How does Callio Therapeutics make money?

One revenue line is on record: pharmaceutical Development.

Who are Callio Therapeutics's main competitors?

Direct peers on record are ProfoundBio, Mersana Therapeutics and Pyxis Oncology. Emerging players are Tubulis, Bolt Biotherapeutics, Heidelberg Pharma and Byondis. Broad incumbents are Daiichi Sankyo, Pfizer (Seagen) and AbbVie (ImmunoGen).

Does Callio Therapeutics have an API?

No public API is recorded for Callio Therapeutics.

What industry is Callio Therapeutics in?

Callio Therapeutics's product category is Oncology Biopharmaceuticals (ADC Therapeutics). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
STATUp and down the ladder: The latest comings and goingsCallio Therapeutics hired Chris Hassig as chief scientific officer, a role he previously held at Boundless Bio. The company's hiring move is highlighted in a weekly feature, with no further details provided.Pulse 2.0Callio Therapeutics Names Zachary Hornby As CEO To Advance Dual-Payload Cancer Drug PipelineCallio Therapeutics appointed Zachary Hornby CEO to advance its dual-payload ADC pipeline. The company's lead candidate CLIO-8221 is in a Phase 1/2 trial for HER2-expressing tumors, with enrollment underway in Australia and the U.S. and plans to expand to China.The Pharma LetterCallio Therapeutics appoints New CEOCallio Therapeutics appointed Zachary Hornby as CEO. Hornby brings experience leading biotech companies through clinical development, financings, and strategic partnerships. The company did not disclose further details about the appointment.GlobeNewswireCallio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026Callio Therapeutics will present preclinical data on CLIO-8221, a dual-payload ADC targeting HER2-expressing tumors, at AACR 2026. The drug combines a Topo1 inhibitor and an ATR inhibitor and is in Phase 1 clinical trials. The company expects the trial to expand to multiple sites in China.BioSpaceCallio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026Callio Therapeutics will present preclinical data on CLIO-8221, a dual-payload ADC targeting HER2-expressing tumors, at AACR 2026. The ADC combines a Topo1 inhibitor and an ATR inhibitor, with a Phase 1 trial ongoing in the US and Australia. Preclinical studies showed potent activity and a broad therapeutic window.citybizCallio Therapeutics Begins Phase I Trial, Dosing First Patient with Dual‑Payload ADC CLIO‑8221 for Advanced HER2‑Positive Solid TumorsCallio Therapeutics has begun dosing the first patient in a Phase I clinical trial evaluating CLIO-8221, a novel dual-payload antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors, with the trial currently underway in Australia and the U.S. following IND clearance from the U.S. FDA, with plans to expand to China after NMPA review. CLIO-8221 is the first program from Callio's dual-payload ADC pipeline to enter the clinic, achieving this milestone within a year of the company's launch, and represents a first-in-class approach combining topoisomerase 1 (Topo1) and ATR inhibitors designed to overcome resistance mechanisms common with single-payload ADCs.GlobeNewswireCallio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid TumorsCallio Therapeutics announced the first patient has been dosed in a Phase I trial of CLIO-8221, a dual-payload HER2-targeted ADC, in Australia and the U.S. The trial is ongoing with IND clearance from the FDA, and expansion to China is planned. The company expects to move its dual-payload ADC pipeline into clinical trials in upcoming months.Silicon Valley Bank​Women's Health Innovation: The Future of HealthcareWomen's health investment funding reached $1.58 billion in 2025, down from a 2024 peak but still representing strong sector momentum, with early-stage median valuations reaching their highest levels since tracking began in 2019. Biopharma, particularly oncology companies focused on breast cancers such as Callio Therapeutics, Iambic, and Lumicell, became the dominant drivers of investment, overtaking healthtech which had previously led the sector. The pending acquisition of Hologic by Blackstone and TPG for an estimated $11 billion, including $700 million in contingent payments tied to breast health revenue, signals growing private equity interest in women's health diagnostics and imaging.American City Business JournalsCallio Therapeutics hunts for Seattle office space after 9-figure launchCallio Therapeutics launched with a $187 million Series A round and is seeking Seattle office space. The biotech, focused on antibody-drug conjugates for cancer, plans to double its six-person team and aims to enter the clinic in under a year.Pulse 2.0Callio Therapeutics: $187 Million (Series A) Secured For Realizing Promise Of Multi-Payload Antibody-Drug ConjugatesCallio Therapeutics closed a $187 million Series A led by Frazier Life Sciences to fund its multi-payload ADC programs. The company will use the proceeds for clinical proof-of-concept of its HER2-targeted dual-payload ADC and an undisclosed program, and entered an exclusive worldwide license with Hummingbird Bioscience.